Scarica l'app Stockscreener
24.29
2.41%
-0.60
Pre-mercato:
23.90
-0.39
-1.61%
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - markets.businessinsider.com
Pacira launches Phase 2 osteoarthritis gene therapy trial - Investing.com
Pacira BioSciences Announces First Patient Dosed in Phase 2 - GlobeNewswire
Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee - MarketScreener
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and ... - Bluefield Daily Telegraph
Game-Changing Knee Osteoarthritis Gene Therapy Advances After 2-Year Pain Relief Success - Stock Titan
Shareholders that lost money on Pacira BioSciences, Inc. (PCRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Teacher Retirement System of Texas Acquires 2,034 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
(PCRX) Technical Data - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Leading Pain Therapy Innovator Pacira Set for Major Investor Presentation at Needham Conference - Stock Titan
Pacira Just Misses Meeting Wall Street’s 2024 Expectations - Orthopedics This Week
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Investors to Inquire about Securities Investigation - markets.businessinsider.com
PNC Financial Services Group Inc. Has $68,000 Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out - Markets Insider
Pacira BioSciences Inc (PCRX) Shares Gap Down to $23.97 on Mar 2 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out - Markets Insider
What is Zacks Research’s Estimate for PCRX FY2027 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Connect - Markets Insider
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Pacira Surges 66.8% in Six Months: How Should You Play the Stock? - Zacks Investment Research
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Commit To Buy Pacira BioSciences At $20, Earn 14.4% Annualized Using Options - Nasdaq
Chronic Pain Market Growth Projections 2024-2034: DelveInsight Analysis | Pacira BioSciences, Paradigm Biopharma, Tonix Pharma - The Globe and Mail
Victory Capital Management Inc. Sells 27,478 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
DOMA Perpetual’s Nomination of Three Highly Qualified Candidates for the Board of Pacira BioSciences - Global Legal Chronicle
Bank of New York Mellon Corp Has $7.47 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $27.22 - Armenian Reporter
Pacira BioSciences: Back On An Uptrend After Positive Developments (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences adopts majority vote standard for director elections By Investing.com - Investing.com Australia
Pacira BioSciences adopts majority vote standard for director elections - Investing.com
Pacira evaluates DOMA board nominees amid growth plans By Investing.com - Investing.com South Africa
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual -March 14, 2025 at 04:13 pm EDT - Marketscreener.com
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual - GlobeNewswire
Pacira Faces Board Challenge as Activist DOMA Pushes for Change Despite New Growth Plan - StockTitan
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences - Morningstar
Class Action Filed Against Pacira BioSciences, Inc. (PCRX)March 14, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. ... - Bluefield Daily Telegraph
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX - GlobeNewswire Inc.
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Pacira BioSciences, Inc. Securities Fraud Class Action - GlobeNewswire
The Gross Law Firm Reminds Pacira BioSciences, Inc. Investors of - GuruFocus.com
Pacira BioSciences, Inc. Investors: Please contact the - GlobeNewswire
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & ... - Bluefield Daily Telegraph
FINAL REMINDER PCRX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Pacira BioSciences, Inc. Investors to Participate in the Class Action Lawsuit - Markets Insider
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $27.22 - Defense World
Pacira BioSciences, Inc. Class Action: The Gross Law Firm Remind - GuruFocus
Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - PR Newswire
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - StreetInsider.com
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, In - GuruFocus.com
FINAL PCRX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Pacira BioSciences, Inc. Investors to Join the Class Action Lawsuit - Markets Insider
(PCRX) On The My Stocks Page - Stock Traders Daily
PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc.PCRX - Business Wire
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
PCRX Shareholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - Markets Insider
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewswire
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
9.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):